PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose
Injection, Type 1, USP) is a sterile, nonpyrogenic solution for fluid and electrolyte
replenishment and caloric supply in a single dose container for intravenous
administration. Each 100 mL contains 5 g Dextrose Hydrous, USP*, 234 mg Sodium
Chloride, USP (NaCl); 128 mg Potassium Acetate, USP (C2H3KO2);
and 32 mg Magnesium Acetate, Tetrahydrate (C4H6MgO4•4H2O).
It contains no antimicrobial agents. pH 5.0 (4.0 to 6.5). The pH is adjusted
with hydrochloric acid.
PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) administered intravenously has value as a source of water, electrolytes, and calories. One liter has an ionic concentration of 40 mEq sodium, 13 mEq potassium, 3 mEq magnesium, 40 mEq chloride, and 16 mEq acetate. The osmolarity is 363 mOsmol/L (calc). Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions ( ≥ 600 mOsmol/L) may cause vein damage. The caloric content is 170 kcal/L.
The flexible container is made with non-latex plastic materials specially designed for a wide range of parenteral drugs including those requiring delivery in containers made of polyolefins or polypropylene. For example, the AVIVA container system is compatible with and appropriate for use in the admixture and administration of paclitaxel. In addition, the AVIVA container system is compatible with and appropriate for use in the admixture and administration of all drugs deemed compatible with existing polyvinyl chloride container systems. The solution contact materials do not contain PVC, DEHP, or other plasticizers.
The suitability of the container materials has been established through biological evaluations, which have shown the container passes Class VI U.S. Pharmacopeia (USP) testing for plastic containers. These tests confirm the biological safety of the container system.
The flexible container is a closed system, and air is prefilled in the container to facilitate drainage. The container does not require entry of external air during administration.
The container has two ports: one is the administration outlet port for attachment
of an intravenous administration set and the other port has a medication site
for addition of supplemental medication (See Directions
for Use). The primary function of the overwrap is to protect the container
from the physical environment.
Last reviewed on RxList: 3/9/2009
This monograph has been modified to include the generic and brand name in many instances.